– Kakao Healthcare and C&R Research Announce Collaboration to Advance Global Clinical Trial Business
[Seoul, South Korea – October 19, 2023] – Kakao Healthcare, under the leadership of CEO Hwang Hee, is proud to announce a strategic business partnership with C&R Research, the pioneering Clinical Research Organization (CRO) in South Korea. This collaboration aims to jointly enhance and expand the global clinical trial business.
In a synergistic approach, Kakao Healthcare will leverage its robust medical big data platform and cutting-edge artificial intelligence technologies, aligning with C&R Research’s extensive expertise in Real-World Data (RWD) and Real-World Evidence (RWE)-based clinical trials. This partnership encompasses a wide spectrum of activities, including identifying international clients, orchestrating clinical trial strategies, and conducting trials. A specific focus of this partnership will be the promotion of clinical trials that harness RWD and RWE, alongside Historical Trial Data (HTD) for comprehensive and data-rich insights.
The global landscape of data-driven clinical research and novel drug development, notably through RWD and RWE, has experienced exponential growth, both internationally and domestically. Government agencies have also established supportive frameworks to facilitate these advancements. In a significant development, in July, both Kakao Healthcare and C&R Research were selected as finalists in the ‘Smart Clinical Trial New Technology Development Research Project,’ alongside Kyung Hee Medical Center. These two entities aspire to play a pivotal role in elevating South Korea’s prominence in the realm of data-driven clinical trials by actively participating in research projects and fostering collaborative ventures.
Hwang Hee, CEO of Kakao Healthcare, expressed his optimism about the collaboration, stating, “We anticipate that this partnership with C&R Research will enable the creation of robust external control clinical trials. Leveraging Kakao Healthcare’s advanced medical big data platform technology, we can execute RWE and RWD-based clinical studies with precision and swiftness.”
Moon-tae Yoon, CEO of C&R Research, emphasized the commitment to creating a universally recognized methodology for establishing external control groups. He stated, “Our collaboration with Kakao Healthcare will focus on developing a robust methodology for constructing external control groups that meet international standards. We are dedicated to acquiring comprehensive expertise in external control group clinical trials, with the objective of positioning C&R Research as the central hub for South Korea’s pharmaceutical and biotechnology companies aiming to expand their global footprint.”
This strategic partnership between Kakao Healthcare and C&R Research marks a significant step towards revolutionizing the clinical trial landscape, with a focus on the integration of data-driven approaches and innovative technologies, ultimately enhancing the quality and efficiency of global clinical research. (End)
